Literature DB >> 17265720

Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs.

Luigi Quintieri1, Marianna Fantin, Csaba Vizler.   

Abstract

Resistance to drugs is a major problem in cancer chemotherapy. Various cellular mechanisms of drug resistance have been identified in cultured tumor cell lines selected for growth in the presence of sublethal concentrations of various anticancer drugs. They involve drug transport and detoxification, qualitative or quantitative alterations of the drug target, repair of drug-induced DNA lesions, and alterations in signaling or execution of apoptosis. More recently, the possibility to simultaneously analyze the expression of thousands of genes using DNA microarrays has allowed exploring the relationships between gene expression and sensitivity to several anticancer drugs. A number of studies using microarrays for identifying genes governing tumor chemosensitivity focused on tumor cell lines. Some clinical studies have also been carried out to investigate whether tumor gene expression patterns could predict clinical response to chemotherapy. Results of these studies are encouraging, indicating that individualization of drug treatment based on multigenic response-predictive markers is feasible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17265720     DOI: 10.1007/978-0-387-39978-2_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  15 in total

Review 1.  Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Mol Cancer Res       Date:  2020-06-05       Impact factor: 5.852

2.  The effects of Livin shRNA on the response to cisplatin in HepG2 cells.

Authors:  Fangfeng Liu; Hong Chang; Wei Xu; Yunpeng Zhai
Journal:  Oncol Lett       Date:  2015-08-25       Impact factor: 2.967

3.  Enhanced RegIV expression predicts the intrinsic 5-fluorouracil (5-FU) resistance in advanced gastric cancer.

Authors:  Li-Sha Ying; Jiang-Liu Yu; Xiao-Xiao Lu; Zhi-Qiang Ling
Journal:  Dig Dis Sci       Date:  2012-09-26       Impact factor: 3.199

4.  Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.

Authors:  Ming-Yii Huang; Joh-Jong Huang; Chun-Ming Huang; Chih-Hung Lin; Hsiang-Lin Tsai; Ching-Wen Huang; Chee-Yin Chai; Chia-Yang Lin; Jaw-Yuan Wang
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

5.  The IncRNA BORG: A novel inducer of TNBC metastasis, chemoresistance, and disease recurrence.

Authors:  Alex J Gooding; Kimberly A Parker; Saba Valadkhan; William P Schiemann
Journal:  J Cancer Metastasis Treat       Date:  2019-05-10

6.  Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Authors:  Yi-Jun Wang; Rishil J Kathawala; Yun-Kai Zhang; Atish Patel; Priyank Kumar; Suneet Shukla; King Leung Fung; Suresh V Ambudkar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-06-14       Impact factor: 5.858

7.  Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells.

Authors:  Chang-Eui Hong; Ae-Kyung Park; Su-Yun Lyu
Journal:  Mol Cell Biochem       Date:  2014-05-31       Impact factor: 3.396

Review 8.  Oncolytic viruses & their specific targeting to tumour cells.

Authors:  Prafull K Singh; Juwar Doley; G Ravi Kumar; A P Sahoo; Ashok K Tiwari
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

9.  MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.

Authors:  X Ding; A B Mohd; Z Huang; T Baba; M Q Bernardini; H K Lyerly; A Berchuck; S K Murphy; A B Buermeyer; G R Devi
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

10.  Using expression and genotype to predict drug response in yeast.

Authors:  Douglas M Ruderfer; David C Roberts; Stuart L Schreiber; Ethan O Perlstein; Leonid Kruglyak
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.